AGRX - Agile Therapeutics Mon 27'th Feb 2017
Stock analysis for Mon 27'th Feb 2017 (Updated daily)
Hold candidate since 2017-02-23
Agile Therapeutics Stock Analysis
Agile Therapeutics gained 2.23% in the last trading day, rising from USD 2.24 to USD 2.29. The price has fallen in 5 of the last 10 days , but is still up by 0.88% over the past 2 weeks. Volume fell in the last day by -80 231 shares and ,in total, 89 924 shares bought and sold for approximately USD 205 926. You should note that falling volume on higher prices causes divergence and may be an early warning about possible changes for the next couple of days.
Agile Therapeutics has broken the very wide and strong falling short-term trend up. Firstly a slower falling rate is indicated, but this may very well be an early signal of a trend shift. On the reaction there will be support on the roof on the current trend broken, which is USD 2.17, a level that may pose a second chance to hit a runner. According to fan-theory USD 4.58 will be the next possible trendtop level and thereby pose a resistancelevel which may not be broken on the first attempt.
A buy signal was issued from a pivot bottom point on Friday February 24, 2017, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Agile Therapeutics holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at USD 2.35 and USD 2.37. A break-up above any of these levels will issue buy signals. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.
Relative Strength Index (RSI)
RSI14 is 50 and the stock is currently not being overbought or oversold
Support & Resistance
Agile Therapeutics finds support from accumulated volume at USD 2.26, USD 2.24, and USD 2.18. On the upside the stock meets some resistance from accumulated volume at USD 2.63, USD 2.52 and USD 2.79.
In general the stock tends to have controlled movements, but the low liquidity has increased the risk substantially.
Our recommended stoploss: USD 2.21 (-3.49%) ( based on support and risk)
Agile Therapeutics holds several negative signals and isolated this should give a sell recommendiation, but due to general chance for a turnaround situation we recommend a hold or accumulate position awaiting further development.